Open AccessThe Effect of Administering Erythropoiesis‐Stimulating Proteins in Patients With Chronic Heart Failure: Results From a Retrospective Study
Author(s) -
Delgado Reynolds M.,
Radovancevic Rajko,
Rossem Charles C.,
Gaemers Sebastiaan J.M.,
Castanes Stratego,
Adams Stephen C.,
Bracey Arthur W.,
Radovancevic Branislav
Publication year - 2006
Publication title -
congestive heart failure
Language(s) - English
Resource type - Journals
eISSN - 1751-7133
pISSN - 1527-5299
DOI - 10.1111/j.1527-5299.2006.05704.x
Subject(s) - medicine , erythropoiesis , anemia , heart failure , blood urea nitrogen , creatinine , hemoglobin , renal function , retrospective cohort study , adverse effect
Anemia is prevalent in patients with chronic heart failure and is associated with worse symptoms and poor prognosis. The authors reviewed the charts of all patients (N=467) treated at Texas Heart Institute from January 2000 to October 2003, during which time a clinical protocol offered treatment with erythropoiesis‐stimulating proteins. Post‐treatment, the authors observed a significant increase in mean ± SD hemoglobin, from 9.9±1.1 g/dL to 11.7±1.5 g/dL ( P <.0001), improvement of renal function (a decrease in mean levels of creatinine and blood urea nitrogen), and fewer hospital admissions (1.0±1.4 vs 1.8±1.6; P =.0003) without an increase in adverse clinical events, compared with pretreatment and compared with an untreated control group. These results suggest a potential benefit of anemia treatment with recombinant erythropoiesis‐stimulating proteins in patients with chronic heart failure.